Health Economic Modelling
We build rigorous cost-effectiveness and budget impact models, integrating real-world data and assumptions to inform reimbursement decisions, payer negotiations, and strategic planning.
Market Access
We help pharmaceutical companies bring their products to the right patients at the right time and right price.
We assist pharmaceutical companies in bringing a new drug to the right patient group promptly and at an optimal price. Our support is always available for Market Access experts, managers, directors, and business units, whether it involves evaluating healthcare interventions, health economic modeling, pricing and reimbursement applications, risk-sharing agreements and models, or market analytics.
What makes our Market Access services unique?
Medaffcon is a full-service provider in Market Access. In our services, we offer strategic and tactical advice and expert services, especially for pharmaceutical companies, covering all phases of market entry and subsequent phases of the product lifecycle.
The goal of Market Access activities is to ensure that new technology, such as a drug, reaches the right patient group as quickly as possible after obtaining marketing authorization at a price that is optimal for healthcare providers, payers, and the marketing authorization holder. This activity aims to mitigate or remove non-medical barriers to the use of technology.
Medaffcon excels in the evaluation of healthcare methods, health economic modeling, pricing and reimbursement applications, interactive tools and calculators, risk-sharing models, and market analysis based on real-life data.
We have carried out dozens of market access projects annually for 15 years, which gives us a broad and insightful expertise. Our active collaboration with authorities, like Fimea, the Pharmaceuticals Pricing Board, and the scientific community ensures that our information is up-to-date and that we can consider the challenges and perspectives of all stakeholders.
Our experts work closely with clients’ Market Access directors, managers, and specialists, as well as business accountables. We provide knowledgeable support, whether it involves the drug pricing and reimbursement application process, strategic market entry planning, or current trends in the pharmaceutical industry.
Our Market Access services
-
-
Pricing and Reimbursement
We guide you through the full reimbursement journey — strategic counsel, dossier crafting, submission, defense, and linkage to evidence generation to secure access under optimal conditions.
-
Interactive value tools
We transform complex clinical, economic, and utilization data into intuitive, stakeholder-facing tools (dashboards, calculators) to support internal decisions, payer dialogue, and external communication.
-
Patient Dynamics
We deliver a reporting tool tracking patient flows and reimbursement data for outpatient medications, enabling sales, marketing, and management to monitor brand performance and market trends.
-
Risk-Sharing Agreements
We design and negotiate performance-based or conditional reimbursement contracts, structuring pricing, evaluation metrics, and risk allocation to accelerate access and balance stakeholder interests.
-
Expert Resourcing
We supply experienced interim professionals to fill gaps in medical or market access teams, manage deliverables, and ensure continuity during organizational transitions.
Medaffcon as Your Market Access partner
Strong Local Expertise and Experience
We are familiar with the local operational environment and national peculiarities, which leads to a smooth Market Access process.
Expert Solutions
We take on an expert role and operate solution-focused throughout all stages of market access projects.
Reliability
We are reliable and honest. We do not overpromise and address critical issues in a timely manner. We advocate for our clients and avoid unnecessary work.
Contact us!
Related articles
-
Patient Dynamics Tool Being Developed for Even Deeper Understanding
Patient Dynamics tool compiles up-to-date and regional data on medicine use in Finland and Sweden.
-
The Nordic countries join forces in HTA medicine assessments
The aim of the cooperation is to harmonize processes and produce joint assessments that each country can use in its own decision-making.
-
The Nordics Should Collaborate in the Life Science Sector
Access times to medicines vary greatly between European countries, and delays in oncology drugs in particular are increasing.
